MedTrace Logo

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

NCT03549000 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 127

Last updated 2024-12-13

No results posted yet for this study

Summary

The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers

Conditions

  • Non-small Cell Lung Cancer (NSCLC)
  • Triple Negative Breast Cancer (TNBC)
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Colorectal Cancer Microsatellite Stable (MSS)
  • Ovarian Cancer
  • Renal Cell Carcinoma (RCC)
  • Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions

OTHER

NZV930

NZV930, Specified dose on specified days, intravenous (IV)

OTHER

PDR001

PDR001, Specified dose on specified days, intravenous (IV)

DRUG

NIR178

NIR178 Specified dose on specified days, Orally

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-18
Primary Completion
2022-10-17
Completion
2022-10-17
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Japan
  • Singapore
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03549000 on ClinicalTrials.gov